Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Garg, 2014, LAMC2 as a therapeutic target for cancers, Expert Opin. Ther. Targets, 18, 979, 10.1517/14728222.2014.934814 Kanojia, 2017, Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets, J. Hematol. Oncol., 10, 173, 10.1186/s13045-017-0540-x Verbaanderd, 2017, Repurposing drugs in oncology: next steps, Trends Cancer, 3, 543, 10.1016/j.trecan.2017.06.007 Aminzadeh-Gohari, 2020, From old to new - repurposing drugs to target mitochondrial energy metabolism in cancer, Semin. Cell Dev. Biol., 98, 211, 10.1016/j.semcdb.2019.05.025 Corsello, 2017, The drug repurposing hub: a next-generation drug library and information resource, Nat. Med., 23, 405, 10.1038/nm.4306 Bertolini, 2015, Drug repurposing in oncology—patient and health systems opportunities, Nat. Rev. Clin. Oncol., 12, 732, 10.1038/nrclinonc.2015.169 Gupta, 2013, Cancer drug discovery by repurposing: teaching new tricks to old dogs, Trends Pharmacol. Sci., 34, 508, 10.1016/j.tips.2013.06.005 Ben Sahra, 2010, The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells, Autophagy, 6, 670, 10.4161/auto.6.5.12434 Kisfalvi, 2009, Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth, Cancer Res., 69, 6539, 10.1158/0008-5472.CAN-09-0418 Alimova, 2009, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell Cycle, 8, 909, 10.4161/cc.8.6.7933 Gotlieb, 2008, In vitro metformin anti-neoplastic activity in epithelial ovarian cancer, Gynecol. Oncol., 110, 246, 10.1016/j.ygyno.2008.04.008 Cantrell, 2010, Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy, Gynecol. Oncol., 116, 92, 10.1016/j.ygyno.2009.09.024 Langley, 2011, Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?, Br. J. Cancer, 105, 1107, 10.1038/bjc.2011.289 Corley, 2003, Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis, Gastroenterology, 124, 47, 10.1053/gast.2003.50008 Yang, 2010, Aspirin use and the risk of gastric cancer: a meta-analysis, Dig. Dis. Sci., 55, 1533, 10.1007/s10620-009-0915-0 Xue, 2018, Review of drug repositioning approaches and resources, Int. J. Biol. Sci., 14, 1232, 10.7150/ijbs.24612 Pushpakom, 2019, Drug repurposing: progress, challenges and recommendations, Nat. Rev. Drug Discov., 18, 41, 10.1038/nrd.2018.168 Hurle, 2013, Computational drug repositioning: from data to therapeutics, Clin. Pharmacol. Ther., 93, 335, 10.1038/clpt.2013.1 Amelio, 2014, DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information, Cell Death Dis., 5, e1051, 10.1038/cddis.2014.9 Talele, 2010, Successful applications of computer aided drug discovery: moving drugs from concept to the clinic, Curr. Top. Med. Chem., 10, 127, 10.2174/156802610790232251 Kitchen, 2004, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat. Rev. Drug Discov., 3, 935, 10.1038/nrd1549 Lamb, 2006, The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 Sanseau, 2012, Use of genome-wide association studies for drug repositioning, Nat. Biotechnol., 30, 317, 10.1038/nbt.2151 Greene, 2016, Pathway and network-based strategies to translate genetic discoveries into effective therapies, Hum. Mol. Genet., 25, R94, 10.1093/hmg/ddw160 Gligorijevic, 2016, Integrative methods for analyzing big data in precision medicine, Proteomics, 16, 741, 10.1002/pmic.201500396 Dai, 2019, Horizontal cell biology: monitoring global changes of protein interaction states with the proteome-wide cellular thermal shift assay (CETSA), Annu. Rev. Biochem., 88, 383, 10.1146/annurev-biochem-062917-012837 Roix, 2014, Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity, PLoS One, 9, e101708, 10.1371/journal.pone.0101708 Kalariya, 2012, Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats, Invest. Ophthalmol. Vis. Sci., 53, 3431, 10.1167/iovs.12-9432 Gonzalez-Angulo, 2010, Metformin: a therapeutic opportunity in breast cancer, Clin. Cancer Res., 16, 1695, 10.1158/1078-0432.CCR-09-1805 Han, 2015, AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell, Cancer Biol. Ther., 16, 77, 10.4161/15384047.2014.987021 Wheaton, 2014, Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis, eLife, 3, e02242, 10.7554/eLife.02242 Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, Bmj, 330, 1304, 10.1136/bmj.38415.708634.F7 Rahmani, 2020, The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials, Clin. Transl. Oncol., 22, 37, 10.1007/s12094-019-02108-9 Dulskas, 2019, Metformin increases cancer specific survival in colorectal cancer patients-National cohort study, Cancer Epidemiol., 62, 101587, 10.1016/j.canep.2019.101587 Mitsuhashi, 2014, Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial, Cancer, 120, 2986, 10.1002/cncr.28853 Mitsuhashi, 2016, Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer, Ann. Oncol., 27, 262, 10.1093/annonc/mdv539 Peng, 2017, Combination of metformin with chemotherapeutic drugs via different molecular mechanisms, Cancer Treat. Rev., 54, 24, 10.1016/j.ctrv.2017.01.005 Babcook, 2014, Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells, Cell Death Dis., 5, e1536, 10.1038/cddis.2014.500 Babcook, 2014, Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer, Mol. Cancer Ther., 13, 2288, 10.1158/1535-7163.MCT-14-0451 Kim, 2019, Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth, Gynecol. Oncol., 154, 432, 10.1016/j.ygyno.2019.05.022 Wang, 2017, Mechanistic study of inhibitory effects of metformin and atorvastatin in combination on prostate cancer cells in vitro and in vivo, Biol. Pharm. Bull., 40, 1247, 10.1248/bpb.b17-00077 Yokoi, 2010, 196, 419 Frohlich, 2015, Chemotherapy and chemoprevention by thiazolidinediones, Biomed Res. Int., 2015, 10.1155/2015/845340 Kitamura, 2001, PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells, Int. J. Cancer, 94, 335, 10.1002/ijc.1470 Shao, 2002, Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells, Cancer Res., 62, 3282 Tontonoz, 1997, Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor, Proc. Natl. Acad. Sci. U. S. A., 94, 237, 10.1073/pnas.94.1.237 Mueller, 1998, Terminal differentiation of human breast cancer through PPAR gamma, Mol. Cell, 1, 465, 10.1016/S1097-2765(00)80047-7 Nishida, 2002, Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma, Br. J. Cancer, 86, 1303, 10.1038/sj.bjc.6600241 Rumi, 2002, Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands, J. Lab. Clin. Med., 140, 17, 10.1067/mlc.2002.125055 Takahashi, 1999, Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells, FEBS Lett., 455, 135, 10.1016/S0014-5793(99)00871-6 Rumi, 2001, Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma, Br. J. Cancer, 84, 1640, 10.1054/bjoc.2001.1821 Heaney, 2003, PPAR-gamma receptor ligands: novel therapy for pituitary adenomas, J. Clin. Invest., 111, 1381, 10.1172/JCI200316575 Cao, 2015, Effects of PPARgamma agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo, Int. J. Clin. Exp. Pathol., 8, 12549 Cellai, 2010, In vivo effects of rosiglitazone in a human neuroblastoma xenograft, Br. J. Cancer, 102, 685, 10.1038/sj.bjc.6605506 Cao, 2009, Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway, Acta Pharmacol. Sin., 30, 1316, 10.1038/aps.2009.119 Mody, 2007, Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202, Endocr. Relat. Cancer, 14, 305, 10.1677/ERC-06-0003 Monami, 2014, Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials, Acta Diabetol., 51, 91, 10.1007/s00592-013-0504-8 Bosetti, 2013, Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis, Oncologist, 18, 148, 10.1634/theoncologist.2012-0302 Turner, 2014, Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis, Br. J. Clin. Pharmacol., 78, 258, 10.1111/bcp.12306 Colmers, 2012, Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis, CMAJ, 184, E675, 10.1503/cmaj.112102 Seabloom, 2017, Fixed-dose combinations of Pioglitazone and metformin for lung cancer prevention, Cancer Prev. Res., 10, 116, 10.1158/1940-6207.CAPR-16-0232 Steudel, 1986, Cerebellar hemangioblastoma (Lindau tumor) in MR tomography, RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 145, 612, 10.1055/s-2008-1049002 Liu, 2019, Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway, Cancer Cell Int., 19, 13, 10.1186/s12935-019-0732-2 Scafoglio, 2015, Functional expression of sodium-glucose transporters in cancer, Proc. Natl. Acad. Sci. U. S. A., 112, E4111, 10.1073/pnas.1511698112 Kaji, 2018, Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake, Int. J. Cancer, 142, 1712, 10.1002/ijc.31193 Hung, 2019, Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced beta-catenin activation, Cell Death Dis., 10, 420, 10.1038/s41419-019-1646-6 Villani, 2016, The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration, Mol. Metab., 5, 1048, 10.1016/j.molmet.2016.08.014 Saito, 2015, Effect of dapagliflozin on colon cancer cell [Rapid Communication], Endocr. J., 62, 1133, 10.1507/endocrj.EJ15-0396 Kuang, 2017, Therapeutic effect of sodium glucose Co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma, Med. Sci. Monit., 23, 3737, 10.12659/MSM.902530 Tang, 2017, SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials, Diabetologia, 60, 1862, 10.1007/s00125-017-4370-8 Ren, 2013, EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors, Prostate, 73, 1453, 10.1002/pros.22692 Choi, 2015, Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression, Br. J. Pharmacol., 172, 5096, 10.1111/bph.13274 Amritha, 2015, Evaluation of anti cancer effects of DPP-4 inhibitors in colon cancer- an invitro study, J. Clin. Diagn. Res.: JCDR, 9, FC14 Femia, 2013, Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats, Int. J. Cancer, 133, 2498, 10.1002/ijc.28260 Jiang, 2018, Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-kappaB activation and inflammatory cytokines, J. Biochem. Mol. Toxicol., 32, 10.1002/jbt.22220 Tseng, 2017, Sitagliptin may reduce breast cancer risk in women with type 2 diabetes, Clin. Breast Cancer, 17, 211, 10.1016/j.clbc.2016.11.002 Tseng, 2017, Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes, Oncotarget, 8, 19057, 10.18632/oncotarget.12137 Tseng, 2017, Sitagliptin and oral cancer risk in type 2 diabetes patients, Oncotarget, 8, 96753, 10.18632/oncotarget.18239 Zhao, 2017, Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials, Sci. Rep., 7, 8273, 10.1038/s41598-017-07921-2 Jang, 2019, The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity, Carcinogenesis, 40, 324, 10.1093/carcin/bgz009 Jang, 2015, Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice, Clin. Exp. Metastasis, 32, 677, 10.1007/s10585-015-9736-z Qin, 2018, Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2, Cancer Lett., 420, 26, 10.1016/j.canlet.2018.01.064 Nishina, 2019, Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice, Cell. Mol. Gastroenterol. Hepatol., 7, 115, 10.1016/j.jcmgh.2018.08.008 Kuhn, 2004, Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs, Front. Biosci., 9, 2605, 10.2741/1420 Banerjee, 2013, Inhibition of proliferation of cervical and leukemic cancer cells by penicillin G, Asian Pac. J. Cancer Prev., 14, 2127, 10.7314/APJCP.2013.14.3.2127 Young, 1981, The anthracycline antineoplastic drugs, N. Engl. J. Med., 305, 139, 10.1056/NEJM198107163050305 Garg, 2017, Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin, Sci. Rep., 7, 9749, 10.1038/s41598-017-10325-x Garg, 2015, Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse, Blood, 126, 2491, 10.1182/blood-2015-05-646240 Lamb, 2015, Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease, Oncotarget, 6, 4569, 10.18632/oncotarget.3174 Scatena, 2018, Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: a clinical pilot study, Front. Oncol., 8, 452, 10.3389/fonc.2018.00452 De Francesco, 2017, Synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs), Oncotarget, 8, 67269, 10.18632/oncotarget.18428 Fiorillo, 2019, Doxycycline, azithromycin and vitamin C. (DAV): a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs), Aging, 11, 2202, 10.18632/aging.101905 Boyle, 2018, Duocarmycin SA, a potent antitumor antibiotic, sensitizes glioblastoma cells to proton radiation, Bioorg. Med. Chem. Lett., 28, 2688, 10.1016/j.bmcl.2018.04.008 Wang, 2019, Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence, BMC Urol., 19, 90, 10.1186/s12894-019-0530-0 Panchuk, 2017, Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E, Free Radic. Biol. Med., 106, 134, 10.1016/j.freeradbiomed.2017.02.024 Boesch, 2016, Ionophore antibiotics as cancer stem cell-selective drugs: open questions, Oncologist, 21, 1291, 10.1634/theoncologist.2016-0159 Vaysberg, 2007, Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression, Transplantation, 83, 1114, 10.1097/01.tp.0000260142.38619.9c Li, 2014, Rapamycin: one drug, many effects, Cell Metab., 19, 373, 10.1016/j.cmet.2014.01.001 Pantziarka, 2015, Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent, Ecancermedicalscience, 9, 521, 10.3332/ecancer.2015.521 Pounds, 2017, Repurposing itraconazole for the treatment of cancer, Oncol. Lett., 14, 2587, 10.3892/ol.2017.6569 Cha, 2012, Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent, PLoS Biol., 10, e1001379, 10.1371/journal.pbio.1001379 Zhang, 2015, Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents, Bioorg. Med. Chem., 23, 3774, 10.1016/j.bmc.2015.03.085 Schmeel, 2017, Griseofulvin efficiently induces apoptosis in in vitro treatment of lymphoma and multiple myeloma, Anticancer Res., 37, 2289, 10.21873/anticanres.11566 Rathinasamy, 2010, Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine, BMC Cancer, 10, 213, 10.1186/1471-2407-10-213 Ho, 2001, Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells, Int. J. Cancer, 91, 393, 10.1002/1097-0215(200002)9999:9999<::AID-IJC1070>3.0.CO;2-# Panda, 2005, Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer, Proc. Natl. Acad. Sci. U. S. A., 102, 9878, 10.1073/pnas.0501821102 Lieby-Muller, 2015, Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives, Bioorg. Med. Chem. Lett., 25, 2078, 10.1016/j.bmcl.2015.03.081 Furtado, 2012, Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis, PLoS One, 7, 10.1371/journal.pone.0030462 Kadavakollu, 2014, Clotrimazole as a cancer drug: a short review, Med. Chem., 4, 722 Robles-Escajeda, 2013, Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells, Cell Biol. Toxicol., 29, 431, 10.1007/s10565-013-9264-z Motawi, 2015, Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells, Chem. Biol. Interact., 233, 147, 10.1016/j.cbi.2015.03.028 Braun, 2020, Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis, Int. J. Cancer, 146, 461, 10.1002/ijc.32709 Zhou, 2010, The antitumor activity of the fungicide ciclopirox, Int. J. Cancer, 127, 2467, 10.1002/ijc.25255 Shen, 2017, Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A, Genes Cancer, 8, 505, 10.18632/genesandcancer.135 Mihailidou, 2018, Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models, Oncotarget, 9, 10360, 10.18632/oncotarget.23164 Zhou, 2019, CPX targeting DJ-1 triggers ROS-induced cell death and protective autophagy in colorectal cancer, Theranostics, 9, 5577, 10.7150/thno.34663 Al-Dali, 2018, Utilizing ethacrynic acid and ciclopirox olamine in liver cancer, Oncol. Lett., 16, 6854 Hoffmann, 2015, Discovery, structure elucidation, and biological characterization of nannocystin A, a macrocyclic myxobacterial metabolite with potent antiproliferative properties, Angew. Chem., 54, 10145, 10.1002/anie.201411377 Krastel, 2015, Nannocystin a: an elongation factor 1 inhibitor from myxobacteria with differential anti-cancer properties, Angew. Chem., 54, 10149, 10.1002/anie.201505069 Zhao, 2017, NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis, Sci. Rep., 7, 1875, 10.1038/s41598-017-01644-0 Brown, 2005, COX-2: a molecular target for colorectal cancer prevention, J. Clin. Oncol., 23, 2840, 10.1200/JCO.2005.09.051 Li, 2000, Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention, cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, Am. Soc. Prev. Oncol., 9, 545 Liao, 2015, Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-kappaB pathway, Clin. Cancer Res., 21, 5349, 10.1158/1078-0432.CCR-15-0198 Xu, 1999, Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate, Proc. Natl. Acad. Sci. U. S. A., 96, 5292, 10.1073/pnas.96.9.5292 Shi, 2017, Aspirin inhibits IKK-beta-mediated prostate cancer cell invasion by targeting matrix metalloproteinase-9 and urokinase-type plasminogen activator, Cell. Physiol. Biochem., 41, 1313, 10.1159/000464434 Din, 2012, Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells, Gastroenterology, 142, 1504, 10.1053/j.gastro.2012.02.050 Alfonso, 2014, Molecular targets of aspirin and cancer prevention, Br. J. Cancer, 111, 61, 10.1038/bjc.2014.271 Shirakawa, 2016, Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity, eLife, 5, 10.7554/eLife.11156 Bashir, 2019, A novel mechanism for the anticancer activity of aspirin and salicylates, Int. J. Oncol., 54, 1256 Zelenay, 2015, Cyclooxygenase-dependent tumor growth through evasion of immunity, Cell, 162, 1257, 10.1016/j.cell.2015.08.015 Markosyan, 2013, Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity, Breast Cancer Res.: BCR, 15, R75, 10.1186/bcr3469 Fujita, 2011, COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells, Cancer Res., 71, 2664, 10.1158/0008-5472.CAN-10-3055 Anani, 2017, Targeting myeloid-derived suppressor cells in cancer, Adv. Exp. Med. Biol., 1036, 105, 10.1007/978-3-319-67577-0_8 Bronger, 2016, CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer, Br. J. Cancer, 115, 553, 10.1038/bjc.2016.172 Na, 2013, Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model, PLoS One, 8, 10.1371/journal.pone.0063451 Hamada, 2017, Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status, J. Clin. Oncol., 35, 1836, 10.1200/JCO.2016.70.7547 Cui, 2014, High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis, Pancreas, 43, 135, 10.1097/MPA.0b013e3182a8d41f Hua, 2019, Complex roles of the old drug aspirin in cancer chemoprevention and therapy, Med. Res. Rev., 39, 114, 10.1002/med.21514 Stabile, 2018, Preclinical evidence for combined use of aromatase inhibitors and NSAIDs as preventive agents of tobacco-induced lung Cancer, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 13, 399, 10.1016/j.jtho.2017.11.126 Tsioulias, 2015, NSAIDs and Colorectal Cancer Control: Promise and Challenges, Curr. Pharmacol. Rep., 1, 295, 10.1007/s40495-015-0042-x Khwaja, 2004, Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein, Cancer Res., 64, 6207, 10.1158/0008-5472.CAN-03-3814 Endo, 2014, Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70, Cell Death Dis., 5, e1027, 10.1038/cddis.2013.550 Ouyang, 2013, A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats, Int. J. Oncol., 42, 643, 10.3892/ijo.2012.1756 Vaish, 2010, The role of NF-kappaB and PPARgamma in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors, Tumour Biol., 31, 427, 10.1007/s13277-010-0051-7 Todo, 2013, Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation, Oncol. Rep., 30, 2379, 10.3892/or.2013.2713 Yue, 2015, Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2, Oncotarget, 6, 21208, 10.18632/oncotarget.4126 De Monte, 2018, Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients, Mol. Clin. Oncol., 8, 504 Inoue, 2004, Molecular mechanism of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome and caspase pathway, Free Radic. Biol. Med., 37, 1290, 10.1016/j.freeradbiomed.2004.07.003 Mayorek, 2010, Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity, PLoS One, 5, 10.1371/journal.pone.0012715 Sareddy, 2013, Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/beta-catenin/Tcf signaling pathway in human glioblastoma cells, Neurochem. Res., 38, 2313, 10.1007/s11064-013-1142-9 Rana, 2015, Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer, Tumour Biol., 36, 5999, 10.1007/s13277-015-3276-7 Zhang, 2000, Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells, Leuk. Res., 24, 385, 10.1016/S0145-2126(99)00198-8 Gerthofer, 2018, Combined modulation of tumor metabolism by metformin and diclofenac in glioma, Int. J. Mol. Sci., 19, 10.3390/ijms19092586 Renner, 2018, Combined metabolic targeting with metformin and the NSAIDs diflunisal and diclofenac induces apoptosis in acute myeloid leukemia cells, Front. Pharmacol., 9, 1258, 10.3389/fphar.2018.01258 Zhou, 2013, The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies, Carcinogenesis, 34, 943, 10.1093/carcin/bgs394 Lubet, 2005, 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin, Carcinogenesis, 26, 571, 10.1093/carcin/bgh352 Bennett, 1987, Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate, Br. J. Pharmacol., 91, 229, 10.1111/j.1476-5381.1987.tb09003.x Maca, 1991, Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro, Anticancer Drug Des., 6, 453 Kobayashi, 1997, Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells, Tohoku J. Exp. Med., 181, 361, 10.1620/tjem.181.361 Mandegary, 2013, Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways, Biomed Res. Int., 2013, 10.1155/2013/237543 Li, 2018, Celecoxib in breast cancer prevention and therapy, Cancer Manag. Res., 10, 4653, 10.2147/CMAR.S178567 Winfield, 2012, Celecoxib and Bcl-2: emerging possibilities for anticancer drug design, Future Med. Chem., 4, 361, 10.4155/fmc.11.177 Kumar, 2016, Unusual anti-leukemia activity of nanoformulated naproxen and other non-steroidal anti-inflammatory drugs, Mater. Sci. Eng. C Mater. Biol. Appl., 69, 1335, 10.1016/j.msec.2016.08.024 Cressey, 2016, The potent inhibitory effect of a naproxen-appended cobalt(III)-Cyclam complex on Cancer stem cells, Chembiochem, 17, 1713, 10.1002/cbic.201600368 Kim, 2014, Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K, Cancer Prev. Res., 7, 236, 10.1158/1940-6207.CAPR-13-0288 Aboul-Fadl, 2014, Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention, Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents, 23, 4177, 10.1007/s00044-014-0979-z Mohammed, 2003, Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer, Mol. Cancer Ther., 2, 183 Campione, 2015, The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors, Drug design, development and therapy, 9, 5843, 10.2147/DDDT.S84849 Silva, 2017, Synergistic effect of carboplatin and piroxicam on two bladder Cancer cell lines, Anticancer Res., 37, 1737, 10.21873/anticanres.11506 Pufall, 2015, Glucocorticoids and Cancer, Adv. Exp. Med. Biol., 872, 315, 10.1007/978-1-4939-2895-8_14 Mattern, 2007, Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy, Cancer Biol. Ther., 6, 1345, 10.4161/cbt.6.9.4765 Lan, 2017, Anti-cancer effects of dopamine in human glioma: involvement of mitochondrial apoptotic and anti-inflammatory pathways, Oncotarget, 8, 88488, 10.18632/oncotarget.19691 Sarkar, 2015, Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia, Int. J. Cancer, 137, 744, 10.1002/ijc.29414 Wang, 2019, The prospective value of dopamine receptors on bio-behavior of tumor, J. Cancer, 10, 1622, 10.7150/jca.27780 Weissenrieder, 2019, Cancer and the Dopamine D.2 Receptor: A Pharmacological Perspective, J. Pharmacol. Exp. Ther., 370, 111, 10.1124/jpet.119.256818 Pellegrino, 2018, FoxO3a mediates the inhibitory effects of the antiepileptic drug lamotrigine on breast Cancer growth, Mol. Cancer Res., 16, 923, 10.1158/1541-7786.MCR-17-0662 Shaw, 2019, Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy, Semin. Cancer Biol. Kang, 2017, Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R, Mol. Cancer Ther., 16, 217, 10.1158/1535-7163.MCT-16-0169-T Yeh, 2012, Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer, Am. J. Respir. Crit. Care Med., 186, 1180, 10.1164/rccm.201207-1180OC Mapes, 2018, Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis, J. Biol. Chem., 293, 2850, 10.1074/jbc.RA117.000162 Chen, 2017, The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma, Oncotarget, 8, 17593, 10.18632/oncotarget.4307 Subramaniam, 2013, Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3, Br. J. Pharmacol., 170, 807, 10.1111/bph.12302 Nelson, 2012, The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations, Genes Cancer, 3, 503, 10.1177/1947601912466555 Ranjan, 2016, Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis, Cancer Res., 76, 877, 10.1158/0008-5472.CAN-15-1233 Reddy, 2015, Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy, Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 117, 308, 10.1016/j.radonc.2015.10.009 Nelson, 2015, The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis, Mol. Cancer, 14, 13, 10.1186/s12943-014-0277-x Aktas, 2015, In vitro effects of phenytoin and DAPT on MDA-MB-231 breast cancer cells, Acta Biochim. Biophys. Sin., 47, 680, 10.1093/abbs/gmv066 Abdelaleem, 2019, Prospects for repurposing CNS drugs for cancer treatment, Oncol. Rev., 13, 411, 10.4081/oncol.2019.411 Kim, 2016, Morphine suppresses lung Cancer cell proliferation through the interaction with opioid growth factor receptor: an in vitro and human lung tissue study, Anesth. Analg., 123, 1429, 10.1213/ANE.0000000000001293 Bimonte, 2015, Morphine promotes tumor angiogenesis and increases breast Cancer progression, Biomed Res. Int., 2015, 161508, 10.1155/2015/161508 Niu, 2015, Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer, Oncotarget, 6, 3963, 10.18632/oncotarget.2894 Khabbazi, 2015, Morphine modulates Interleukin-4- or breast Cancer Cell-induced pro-metastatic activation of macrophages, Sci. Rep., 5, 11389, 10.1038/srep11389 Wang, 2015, The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells, Exp. Hematol. Oncol., 4, 5, 10.1186/2162-3619-4-5 Liu, 2017, Caffeine induces sustained apoptosis of human gastric cancer cells by activating the caspase9/caspase3 signalling pathway, Mol. Med. Rep., 16, 2445, 10.3892/mmr.2017.6894 Kaplanek, 2015, Caffeine-hydrazones as anticancer agents with pronounced selectivity toward T-lymphoblastic leukaemia cells, Bioorg. Chem., 60, 19, 10.1016/j.bioorg.2015.03.003 Peak, 2016, The role of PDE5 inhibitors and the NO/cGMP pathway in Cancer, Sex. Med. Rev., 4, 74, 10.1016/j.sxmr.2015.10.004 Shi, 2011, Roles of sildenafil in enhancing drug sensitivity in cancer, Cancer Res., 71, 3735, 10.1158/0008-5472.CAN-11-0375 Mei, 2015, Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo, Am. J. Cancer Res., 5, 3311 Islam, 2017, Sildenafil suppresses inflammation-driven colorectal Cancer in mice, Cancer Prev. Res., 10, 377, 10.1158/1940-6207.CAPR-17-0015 Booth, 2014, Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells, Mol. Pharmacol., 85, 408, 10.1124/mol.113.090043 Booth, 2015, PDE5 inhibitors enhance celecoxib killing in multiple tumor types, J. Cell. Physiol., 230, 1115, 10.1002/jcp.24843 Greish, 2018, Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer, J. Drug Target., 26, 610, 10.1080/1061186X.2017.1405427 Webb, 2015, Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance, Cancer Biol. Ther., 16, 1660, 10.1080/15384047.2015.1099769 Noonan, 2014, Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma, Cancer Immunol. Res., 2, 725, 10.1158/2326-6066.CIR-13-0213 Tobin, 2017, The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients, J. Leukoc. Biol., 102, 381, 10.1189/jlb.5VMR1016-449R Li, 2014, Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells, Pharm. Res., 31, 86, 10.1007/s11095-013-1134-0 Black, 2008, PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model, Brain Res., 1230, 290, 10.1016/j.brainres.2008.06.122 Liu, 2016, Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway, Cancer Lett., 378, 38, 10.1016/j.canlet.2016.05.010 Tinsley, 2011, Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells, Cancer Prev. Res., 4, 1275, 10.1158/1940-6207.CAPR-11-0095 Li, 2013, Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling, Mol. Cancer Ther., 12, 1848, 10.1158/1535-7163.MCT-13-0048 Ding, 2011, The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter, PLoS One, 6, e19329, 10.1371/journal.pone.0019329 Pantziarka, 2018, Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents, Ecancermedicalscience, 12, 824, 10.3332/ecancer.2018.824 Zheng, 2017, Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1, Oncotarget, 8, 44255, 10.18632/oncotarget.17464 Yen, 2010, Cancer-associated IDH mutations: biomarker and therapeutic opportunities, Oncogene, 29, 6409, 10.1038/onc.2010.444 Yaz, 2004, Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro, Am. J. Clin. Oncol., 27, 384, 10.1097/01.COC.0000071945.15623.C6 Triscott, 2012, Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide, Oncotarget, 3, 1112, 10.18632/oncotarget.604 Tan, 2018, Drug repositioning in glioblastoma: a pathway perspective, Front. Pharmacol., 9, 218, 10.3389/fphar.2018.00218 Liu, 2012, Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells, Br. J. Cancer, 107, 1488, 10.1038/bjc.2012.442 Rana, 2006, Small interference RNA-mediated knockdown of sperm associated antigen 9 having structural homology with c-Jun N-terminal kinase-interacting protein, Biochem. Biophys. Res. Commun., 340, 158, 10.1016/j.bbrc.2005.11.168 Paranjpe, 2014, Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage, Carcinogenesis, 35, 692, 10.1093/carcin/bgt366 Kim, 2017, Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells, Biochem. Biophys. Res. Commun., 486, 1069, 10.1016/j.bbrc.2017.03.164 Li, 2018, Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-kappaB and TGF-beta pathways, J. Cell. Mol. Med., 22, 439, 10.1111/jcmm.13334 Park, 2018, Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death, PLoS One, 13, 10.1371/journal.pone.0203069 Song, 2016, Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance, J. Control. Release, 231, 94, 10.1016/j.jconrel.2016.02.039 Pantziarka, 2014, Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent, Ecancermedicalscience, 8, 443, 10.3332/ecancer.2014.485 Mukhopadhyay, 2002, Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo, Clin. Cancer Res., 8, 2963 Bai, 2011, Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme, Neurooncology, 13, 974 Nygren, 2013, Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer, J. Cancer Res. Clin. Oncol., 139, 2133, 10.1007/s00432-013-1539-5 Sawanyawisuth, 2014, Effect of the antiparasitic drug mebendazole on cholangiocarcinoma growth, Southeast Asian J. Trop. Med. Public Health, 45, 1264 Celestino Pinto, 2017, Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis, Toxicol. In Vitro, 43, 87, 10.1016/j.tiv.2017.06.007 Melotti, 2014, The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer, EMBO Mol. Med., 6, 1263, 10.15252/emmm.201404084 Drinyaev, 2004, Antitumor effect of avermectins, Eur. J. Pharmacol., 501, 19, 10.1016/j.ejphar.2004.08.009 Hashimoto, 2009, Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines, Drug Discov. Ther., 3, 243 Zhu, 2017, Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage, Biochem. Biophys. Res. Commun., 492, 373, 10.1016/j.bbrc.2017.08.097 Wang, 2016, Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer, Autophagy, 12, 2498, 10.1080/15548627.2016.1231494 Nambara, 2017, Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer, Oncotarget, 8, 107666, 10.18632/oncotarget.22587 Jiang, 2019, Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-kappaB pathway, J. Exp. Clin. Cancer Res., 38, 265, 10.1186/s13046-019-1251-7 Dominguez-Gomez, 2018, Ivermectin as an inhibitor of cancer stemlike cells, Mol. Med. Rep., 17, 3397 Stein, 1989, Suramin: an anticancer drug with a unique mechanism of action, J. Clin. Oncol., 7, 499, 10.1200/JCO.1989.7.4.499 Di Santo, 2014, A functional perspective of nitazoxanide as a potential anticancer drug, Mutat. Res., 768, 16, 10.1016/j.mrfmmm.2014.05.005 Cao, 2013, The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity, J. Biol. Chem., 288, 34181, 10.1074/jbc.M113.472563 Priotti, 2018, Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast Cancer, AAPS PharmSciTech, 19, 3734, 10.1208/s12249-018-1169-y Gupta, 2019, Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2/beta-Catenin signaling, Mol. Cancer Ther., 18, 1708, 10.1158/1535-7163.MCT-18-1286 Fiorillo, 2016, Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells, Oncotarget, 7, 34084, 10.18632/oncotarget.9122 Chen, 2018, Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy, J. Biochem. Mol. Toxicol., 32, 10.1002/jbt.22195 Tian, 2018, Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer, Biochem. Biophys. Res. Commun., 499, 1019, 10.1016/j.bbrc.2018.04.042 Lv, 2018, Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer, J. Bioenerg. Biomembr., 50, 263, 10.1007/s10863-018-9755-y Wang, 2015, The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer, J. Pharmacol. Exp. Ther., 352, 129, 10.1124/jpet.114.218644 Verbaanderd, 2017, Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents, Ecancermedicalscience, 11, 781, 10.3332/ecancer.2017.781 Choi, 2014, Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1, Stem Cells, 32, 2309, 10.1002/stem.1746 Balic, 2014, Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling, Mol. Cancer Ther., 13, 1758, 10.1158/1535-7163.MCT-13-0948 Shimizu, 2012, Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma, Int. J. Cancer, 131, 548, 10.1002/ijc.26374 Sehgal, 2015, You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia, Leukemia, 29, 517, 10.1038/leu.2014.349 Manic, 2014, Chloroquine and hydroxychloroquine for cancer therapy, Mol. Cell. Oncol., 1 Katz, 1985, Effects of digitalis on cell biochemistry: sodium pump inhibition, J. Am. Coll. Cardiol., 5, 16A, 10.1016/S0735-1097(85)80459-9 Schneider, 2017, Anticancer and immunogenic properties of cardiac glycosides, Molecules, 22, 10.3390/molecules22111932 Raghavendra, 2007, Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases, Apoptosis, 12, 307, 10.1007/s10495-006-0626-3 Ye, 2011, Cardiac glycosides are potent inhibitors of interferon-beta gene expression, Nat. Chem. Biol., 7, 25, 10.1038/nchembio.476 Bielawski, 2006, Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A, Biol. Pharm. Bull., 29, 1493, 10.1248/bpb.29.1493 Zhang, 2008, Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth, Proc. Natl. Acad. Sci. U.S.A., 105, 19579, 10.1073/pnas.0809763105 Perne, 2009, Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis, PLoS One, 4, e8292, 10.1371/journal.pone.0008292 Prassas, 2011, Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks, Mol. Cancer Ther., 10, 2083, 10.1158/1535-7163.MCT-11-0421 McConkey, 2000, Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells, Cancer Res., 60, 3807 Stenkvist, 1999, Is digitalis a therapy for breast carcinoma?, Oncol. Rep., 6, 493 Xie, 2017, Digitalis use and risk of gastrointestinal cancers: a nationwide population-based cohort study, Oncotarget, 8, 34727, 10.18632/oncotarget.16151 Osman, 2017, Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies, PLoS One, 12, 10.1371/journal.pone.0178611 Shiozaki, 2006, Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state, J. Physiol. Sci., 56, 401, 10.2170/physiolsci.RP010806 Liu, 2019, Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study, BMC Cancer, 19, 1017, 10.1186/s12885-019-6242-8 Haas, 2010, Inhibition of the Sodium-Potassium-Chloride Cotransporter Isoform-1 reduces glioma invasion, Cancer Res., 70, 5597, 10.1158/0008-5472.CAN-09-4666 Iwamoto, 2004, Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation, American journal of physiology, Lung cellular and molecular physiology, 287, L510, 10.1152/ajplung.00021.2004 Panet, 1991, Stimulation of bumetanide-sensitive Na+/K+/Cl- cotransport by different mitogens in synchronized human skin fibroblasts is essential for cell proliferation, J. Cell Biol., 114, 337, 10.1083/jcb.114.2.337 Kourghi, 2016, Bumetanide derivatives AqB007 and AqB011 selectively block the Aquaporin-1 ion channel conductance and slow Cancer cell migration, Mol. Pharmacol., 89, 133, 10.1124/mol.115.101618 Tomita, 2019, Bumetanide-derived aquaporin 1 inhibitors, AqB013 and AqB050 inhibit tube formation of endothelial cells through induction of apoptosis and impaired migration in vitro, Int. J. Mol. Sci., 20, 10.3390/ijms20081818 Pantziarka, 2016, Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent, Ecancermedicalscience, 10, 680 Rico, 2017, Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models, Oncotarget, 8, 2874, 10.18632/oncotarget.13760 Brohee, 2018, Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression, Sci. Rep., 8, 7050, 10.1038/s41598-018-25340-9 Talarico, 2016, Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells, Sci. Rep., 6, 18673, 10.1038/srep18673 Dale, 2006, Statins and cancer risk: a meta-analysis, Jama, 295, 74, 10.1001/jama.295.1.74 Kuoppala, 2008, Statins and cancer: A. systematic review and meta-analysis, Eur. J. Cancer, 44, 2122, 10.1016/j.ejca.2008.06.025 Weis, 2002, Statins have biphasic effects on angiogenesis, Circulation, 105, 739, 10.1161/hc0602.103393 Sivaprasad, 2006, Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells, Mol. Cancer Ther., 5, 2310, 10.1158/1535-7163.MCT-06-0175 Goc, 2012, Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis, BMC Cancer, 12, 409, 10.1186/1471-2407-12-409 Spampanato, 2012, Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression, Int. J. Oncol., 40, 935, 10.3892/ijo.2011.1273 Glynn, 2008, The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells, BMC Cancer, 8, 9, 10.1186/1471-2407-8-9 Archibugi, 2019, Statin use is associated to a reduced risk of pancreatic cancer: a meta-analysis, Dig. Liver Dis., 51, 28, 10.1016/j.dld.2018.09.007 Bansal, 2012, Statin use and risk of prostate cancer: a meta-analysis of observational studies, PLoS One, 7, 10.1371/journal.pone.0046691 Islam, 2017, Exploring association between statin use and breast cancer risk: an updated meta-analysis, Arch. Gynecol. Obstet., 296, 1043, 10.1007/s00404-017-4533-3 Babcook, 2016, Statin use in prostate Cancer: an update, Nutr. Metab. Insights, 9, 43, 10.4137/NMI.S38362 Tan, 2020, Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer, Cancer Med., 9, 2379, 10.1002/cam4.2862 Goldfarb, 1994, Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma, J. Urol., 151, 208, 10.1016/S0022-5347(17)34918-2 Fujimoto, 2001, Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist, FEBS Lett., 495, 197, 10.1016/S0014-5793(01)02377-8 Suganuma, 2005, Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination, Clin. Cancer Res., 11, 2686, 10.1158/1078-0432.CCR-04-1946 Herr, 2008, Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer, Gynecol. Oncol., 109, 418, 10.1016/j.ygyno.2008.02.019 Anandanadesan, 2008, Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling, J. Gastrointest. Surg., 12, 57, 10.1007/s11605-007-0403-9 Yasumatsu, 2004, Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells, J. Cancer Res. Clin. Oncol., 130, 567, 10.1007/s00432-004-0582-7 Ishida, 2016, Repurposing of approved cardiovascular drugs, J. Transl. Med., 14, 269, 10.1186/s12967-016-1031-5 Regulska, 2019, Beyond the boundaries of cardiology: still untapped anticancer properties of the cardiovascular system-related drugs, Pharmacol. Res., 147, 10.1016/j.phrs.2019.104326 Attoub, 2008, Captopril as a potential inhibitor of lung tumor growth and metastasis, Ann. N. Y. Acad. Sci., 1138, 65, 10.1196/annals.1414.011 Koh, 2014, Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver, Clin. Exp. Metastasis, 31, 395, 10.1007/s10585-014-9635-8 George, 2010, The renin-angiotensin system and cancer: old dog, new tricks, Nature reviews, Cancer, 10, 745 Hu, 2015, KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro, Int. J. Clin. Exp. Pathol., 8, 9182 Juillerat-Jeanneret, 2004, Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma, Br. J. Cancer, 90, 1059, 10.1038/sj.bjc.6601646 Pinter, 2017, Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy, Sci. Transl. Med., 9, 10.1126/scitranslmed.aan5616 Bertolesi, 2002, The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms, Mol. Pharmacol., 62, 210, 10.1124/mol.62.2.210 Das, 2013, T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells, Pigment Cell Melanoma Res., 26, 874, 10.1111/pcmr.12155 Bui, 2008, The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil, Drug Metab. Dispos., 36, 1291, 10.1124/dmd.107.020115 Kondo, 1995, Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells, Br. J. Cancer, 71, 282, 10.1038/bjc.1995.57 Taylor, 1992, Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse, Cancer Res., 52, 2413 Jensen, 2001, Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice, Surg. Neurol., 55, 275, 10.1016/S0090-3019(01)00444-X Millward, 1993, Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study, Br. J. Cancer, 67, 1031, 10.1038/bjc.1993.189 Yoshida, 2003, Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells, Eur. J. Pharmacol., 472, 23, 10.1016/S0014-2999(03)01831-4 Dalton, 1995, A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma, A Southwest Oncology Group study, Cancer, 75, 815 Gandini, 2018, Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis, Crit. Rev. Oncol. Hematol., 122, 1, 10.1016/j.critrevonc.2017.12.003 Huang, 2017, Nitric oxide donor-based Cancer therapy: advances and prospects, J. Med. Chem., 60, 7617, 10.1021/acs.jmedchem.6b01672 Sukhatme, 2015, Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent, Ecancermedicalscience, 9, 568, 10.3332/ecancer.2015.568 Pipili-Synetos, 1995, Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate, Br. J. Pharmacol., 116, 1829, 10.1111/j.1476-5381.1995.tb16670.x Wang, 2015, Synergistic apoptosis-inducing effect of aspirin and isosorbide mononitrate on human colon cancer cells, Mol. Med. Rep., 12, 4750, 10.3892/mmr.2015.3963 Driffort, 2014, Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization, Mol. Cancer, 13, 264, 10.1186/1476-4598-13-264 Lee, 2019, Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: effects of combination with ranolazine, J. Cell. Physiol., 234, 23066, 10.1002/jcp.28868 Bugan, 2019, Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate, Prostate Cancer Prostatic Dis., 22, 569, 10.1038/s41391-019-0128-3 Suckow, 2004, The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice, Cancer Lett., 209, 165, 10.1016/j.canlet.2004.01.007 Jan, 2001, Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells, Cancer Chemother. Pharmacol., 48, 37, 10.1007/s002800000262 Wang, 2001, The anti-anginal drug fendiline increases intracellular Ca(2+) levels in MG63 human osteosarcoma cells, Toxicol. Lett., 119, 227, 10.1016/S0378-4274(01)00262-4 Jan, 2001, Dual effect of the antianginal drug fendiline on bladder female transitional carcinoma cells: mobilization of intracellular CA2+ and induction of cell death, Pharmacology, 62, 218, 10.1159/000056098 Cheng, 2001, Effects of the antianginal drug fendiline on Ca2+ movement in hepatoma cells, Hum. Exp. Toxicol., 20, 359, 10.1191/096032701680350523 Cui, 2017, Targeting calcium signaling in cancer therapy, Acta Pharm. Sin. B, 7, 3, 10.1016/j.apsb.2016.11.001 van der Hoeven, 2013, Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission, Mol. Cell. Biol., 33, 237, 10.1128/MCB.00884-12 Woods, 2015, Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and beta-catenin signaling, Oncotarget, 6, 35931, 10.18632/oncotarget.5933 Alhothali, 2019, Fendiline enhances the cytotoxic effects of therapeutic agents on PDAC cells by inhibiting tumor-promoting signaling events: a potential strategy to combat PDAC, Int. J. Mol. Sci., 20, 10.3390/ijms20102423